Aspergillus Galactomannan Titer as a Diagnostic Marker of Invasive Pulmonary Aspergillosis in Lung Transplant Recipients: A Single-Center Retrospective Cohort Study
Authors:
- Eun-Young KimEKEun-Young Kim
- Seung-Hyun YongSYSeung-Hyun Yong
- Min-Dong SungMSMin-Dong Sung
- A-La WooAWA-La Woo
- Young-Mok ParkYPYoung-Mok Park
- Ha-Eun KimHKHa-Eun Kim
- Su-Jin JungSJSu-Jin Jung
- Song-Yee KimSKSong-Yee Kim
- Jin-Gu LeeJLJin-Gu Lee
- Young-Sam KimYKYoung-Sam Kim
- Hyo-Chae PaikHPHyo-Chae Paik
- Moo-Suk ParkMPMoo-Suk Park
Open Access
- 28 April 2023
- journal article
- research article
- Published by MDPI AG in Journal of Fungi
- Vol. 9 (5) , 527
Abstract
Invasive pulmonary aspergillosis (IPA) can occur in immunocompromised patients, and an early detection and intensive treatment are crucial. We sought to determine the potential of Aspergillus galactomannan antigen titer (AGT) in serum and bronchoalveolar lavage fluid (BALF) and serum titers of beta-D-glucan (BDG) to predict IPA in lung transplantation recipients, as opposed to pneumonia unrelated to IPA. We retrospectively reviewed the medical records of 192 lung transplant recipients. Overall, 26 recipients had been diagnosed with proven IPA, 40 recipients with probable IPA, and 75 recipients with pneumonia unrelated to IPA. We analyzed AGT levels in IPA and non-IPA pneumonia patients and used ROC curves to determine the diagnostic cutoff value. The Serum AGT cutoff value was 0.560 (index level), with a sensitivity of 50%, specificity of 91%, and AUC of 0.724, and the BALF AGT cutoff value was 0.600, with a sensitivity of 85%, specificity of 85%, and AUC of 0.895. Revised EORTC suggests a diagnostic cutoff value of 1.0 in both serum and BALF AGT when IPA is highly suspicious. In our group, serum AGT of 1.0 showed a sensitivity of 27% and a specificity of 97%, and BALF AGT of 1.0 showed a sensitivity of 60% and a specificity of 95%. The result suggested that a lower cutoff could be beneficial in the lung transplant group. In multivariable analysis, serum and BALF AGT, with a minimal correlation between the two, showed a correlation with a history of diabetes mellitus.Keywords
This publication has 24 references indexed in Scilit:
- Invasive pulmonary Aspergillosis in organ transplants – Focus on lung transplantsRespiratory Investigation, 2016
- Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trialThe Lancet, 2016
- Point-Counterpoint: β- d -Glucan Testing Is Important for Diagnosis of Invasive Fungal InfectionsJournal of Clinical Microbiology, 2013
- The utility of galactomannan antigen in the bronchial washing and serum for diagnosing pulmonary aspergillosisRespiratory Medicine, 2013
- Detection of Galactomannan in Bronchoalveolar Lavage Fluid Samples of Patients at Risk for Invasive Pulmonary Aspergillosis: Analytical and Clinical ValidityJournal of Clinical Microbiology, 2012
- The impact of invasive fungal diseases on survival after lung transplantationClinical Transplantation, 2010
- Invasive Fungal Infections among Organ Transplant Recipients: Results of the Transplant‐Associated Infection Surveillance Network (TRANSNET)Clinical Infectious Diseases, 2010
- Posaconazole as salvage treatment of invasive fungal infections in patients with underlying renal impairmentJournal of Antimicrobial Chemotherapy, 2008
- Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus GroupClinical Infectious Diseases, 2008
- AspergillusInfections in Transplant RecipientsClinical Microbiology Reviews, 2005